Skip to main content

Table 1 Patient characteristics

From: Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer

Characteristics Overall population (n = 20) CC-0 (n = 16) CC-1+ (n = 14) p-value Relapse < 6 months (n = 12) Relapse > 6 months (n = 18) p-value
Age (years) 62.8 +/− 10.77 63.62 +/− 8.62 61.93 +/− 13.09 0.92 63.57 +/− 11.95 62.2 +/− 9.97 0.63
BMI (kg/m2) 23.64 +/− 3.39 23.69 +/− 2.91 23.59 +/− 3.98 0.77 22.75 +/− 3.04 24.42 +/− 3.58 0.24
Gestity 1.81 +/− 1.49 1.94 +/− 1.95 1.64 +/− 1.69 0.45 1.23 +/− 1.47 1.80 +/− 1.57 0.90
Parity 1.74 +/− 1.65 1.75 +/− 1.24 1.73 +/− 2.20 0.51 1.92 +/− 1.98 1.60 +/− 1.40 0.86
Menopause 27 (90 %) 15 (93.7 %) 12 (85.7 %) 0.59 10 (83.3 %) 17 (94.4 %) 0.59
FIGO stage     1    0.63
 IIIa 1 (3.31 %) 1 (6.25 %) 0   0 1 (5.55 %)  
 IIIb 1 (3.31 %) 1 (6.25 %) 0   0 1 (5.55 %)  
 IIIc 23 (76.7 %) 12 (75 %) 11 (78.6 %)   9 (75 %) 14 (77.8 %)  
 IV 5 (16.67 %) 2 (12.5 %) 3 (21.4 %)   3 (25 %) 2 (11.1 %)  
Grading     0.26    0.63
 I 3 (10 %) 3 (18.7 %) 0   0 3 (16.7 %)  
 II 9 (30 %) 5 (31.3 %) 4 (35.7 %)   5 (41.7 %) 4 (22.2 %)  
 III 15 (50 %) 6 (37.5 %) 9 (64.3 %)   5 (41.7 %) 10 (55.6 %)  
Pre-NAC CA-125 (UI/ml) 1762.63 [16–9453] 1432.89 [16–9453] 2257.25 [302–9400] 0.05 1884.07 [16–9453] 1656.8 [57–9400] 0.15
Pre-NAC HE4 (pmol/l) 985.3 [46.1–6562] 928.22 [46.1–6562] 984.26 [153.2–2746] 0.24 1374.59 [63.9–6562] 644.66 [46.1–2031] 0.13
Cycles of NAC 5.75 [3–7] 5.5 [3–6] 6.12 [6–7] 0.08 5.60 [3–7] 5.62 [4–6] 0.69
  1. CC-0 non residual disease after interval debulking surgery (IDS), CC-1+ residual disease after IDS
  2. BMI body mass index, FIGO International Federation of Gynecology and Obstetrics, NAC neoadjuvant chemotherapy